Pricing Log in Create free account
Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

CYTK Healthcare Biotechnology

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue
+2,356.5%
EPS
+46.3%
Free cash flow
−6.73%
Total debt
−83.9%

Quarter to September 2026, against a year earlier

54.10 1.45 −2.61%
Market cap
$7.7B
P/E
0.0×
Fwd P/E
−10.3×
Dividend yield
—
F-score
2/9
Altman Z
−1.98
Beneish M
−0.44
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cytokinetics, Incorporated 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:30 PM ET · Document on sec.gov · Filing index

Red flags

  • Short cash runway

    Cytokinetics, Incorporated’s cash and short-term investments cover about 1.4 quarters of its operating cash burn

    10-Q filed · The filing · sec.gov

  • Share dilution

    Shares outstanding rose 13.9% in a year, to 139.3 million

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Nov 5, 2025: 45 added · 37 removed · 55 modified; 8 with only figures updated; 5 moved without change